Surrozen Q3 2021 net loss $14.0M; cash $135.4M post business combination

Surrozen, Inc./DE

2022-Q3 EPS reported -$1.86

Cash, cash equivalents and marketable securities $135.4M as of Sept 30, 2021, up from $18.9M at June 30, 2021.
Net loss of $14.0M for Q3 2021 vs $8.6M in Q3 2020; R&D expenses $10.4M (Q3 2021) vs $7.0M.
Plan to initiate Phase 1a trials for SZN-1326 (ulcerative colitis) and SZN-043 (alcoholic hepatitis) in 2022.
Pre-clinical data for both candidates presented at medical congresses; five new discovery programs initiated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.